RxDoctor Payments Data

Mohamad Mokadem, MD

Gastroenterology · Iowa City, IANPI 1386803187

Payments from drug & device makers

What this record shows

4 manufacturers reported payments, led by Novo Nordisk at 59.2% of the total. Reporting peaked in 2022 at $725 and has fallen 76.9% since, to $168 in 2025.

$1,031in general payments, 2019–2025

Across 22 payments — averaging $46.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$610
  • Medtronic$253
  • Boston Scientific$98
  • Phathom Pharmaceuticals, Inc.$69
$197,498in research payments, 2019–2025

Across 3 payments — averaging $65,833 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$197K

What the payments were for

  • Food & beverage$51550%
  • Education$51650%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,031 in reported general payments places this provider in the 60th percentile of 113 gastroenterology providers in Iowa.

See all gastroenterology providers in Iowa

Medicare billing

Part B allowed, 2024
$31,801
Medicare patients
197
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$78,028
OzempicSemaglutide37$41,238
XifaxanRifaximin22$32,967
MounjaroTirzepatide20$19,943
Dexlansoprazole DrDexlansoprazole29$4,265
Famotidine39$557
Esomeprazole Magnesium18$509
Omeprazole30$319
Metformin Hcl26$218
Sucralfate12$200
Topiramate48$121
Bupropion Hcl SrBupropion Hcl11$117
Promethazine Hcl13$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$610$41,23837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 113 gastroenterology providers in Iowa.

Other gastroenterology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →